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Abstract
Background: The dual specificity phosphatase cdc25C was the first human cdc25 family member found to be essential in
the activation of cdk1/cyclin B1 that takes place at the entry into mitosis. Human cdc25C is phosphorylated on Proline-
dependent SP and TP sites when it becomes active at mitosis and the prevalent model is that this phosphorylation/
activation of cdc25C would be part of an amplification loop with cdk1/cyclin B1.
Methodology/Principal Findings: Using highly specific antibodies directed against cdc25C phospho-epitopes, pT67 and
pT130, we show here that these two phospho-forms of cdc25C represent distinct pools with differential localization during
human mitosis. Phosphorylation on T67 occurs from prophase and the cdc25C-pT67 phospho-isoform closely localizes with
condensed chromosomes throughout mitosis. The phospho-T130 form of cdc25C arises in late G2 and associates
predominantly with centrosomes from prophase to anaphase B where it colocalizes with Plk1. As shown by
immunoprecipitation of each isoform, these two phospho-forms are not simultaneously phosphorylated on the other
mitotic TP sites or associated with one another. Phospho-T67 cdc25C co-precipitates with MPM2-reactive proteins while
pT130-cdc25C is associated with Plk1. Interaction and colocalization of phosphoT130-cdc25C with Plk1 demonstrate in
living cells, that the sequence around pT130 acts as a true Polo Box Domain (PBD) binding site as previously identified from
in vitro peptide screening studies. Overexpression of non-phosphorylatable alanine mutant forms for each isoform, but not
wild type cdc25C, strongly impairs mitotic progression showing the functional requirement for each site-specific
phosphorylation of cdc25C at mitosis.
Conclusions/Significance: These results show for the first time that in human mitosis, distinct phospho-isoforms of cdc25C
exist with different localizations and interacting partners, thus implying that the long-standing model of a cdc25C/cdk1
multi-site auto amplification loop is implausible.
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Introduction
Mammalian cell mitosis is a dynamic process involving
inactivation of interphase signaling pathways and activation of
mitotic kinases, particularly cyclin dependent kinases (cdks)
[reviews 1, 2]. Amongst mitotic cdks, cdk1 and 2 are the most
closely investigated, with cdk2-cyclin A2 functioning in late G2
and prophase and cdk1/cyclin B1 modulating progression to
metaphase [reviewed 3]. Activation of cdk1-cyclin B1 involves
various events including phosphorylation of threonine 161 (T161)
on cdk1 [4, reviewed 1]; nuclear localization of cyclin B1
[reviewed 5], phosphorylation of cyclin B1 [6] and dephosphor-
ylation of two negative regulatory sites T14 and Y15 on cdk1
[reviewed 1]. Dual specificity phosphatases required for the latter,
are members of the cdc25 family [reviewed 7]. Humans have three
different cdc25 proteins, cdc25A, B and C and all have been
implicated in mitotic activation [8–11, respectively]. Human
cdc25C was the first phosphatase identified in dephosphorylation
of cdk1 [12] and is itself modulated by phosphorylation [13–17]
and localization [reviewed 18]. Human cdc25C is also subject to
alternative splicing in some cell types [19,20]. At G2/M, cdc25C
localizes in the nucleus in coordination with cyclin B1 [21] and at
the centrosomes [22] and undergoes dephosphorylation of
negative regulatory sites including serine 216 [23] and phosphor-
ylation on at least 6 residues in human cdc25C, S/TP sites
threonines (T) 48, 67, 130 and serine (S) 214 [17] and Plk1 sites
S191 and S198 [24]. In transformed Hela cells, phosphorylation of
S214 and S216 has been implicated in a ying/yang mechanism
with phosphorylation of S214 bringing about the timely entry into
mitosis [25]. Phosphorylation of S198 by Plk1 promotes cdc25C
nuclear localization [21] and a proteomic screen of phospho-
peptides interacting with the Plk1 binding domain identified a
S-phosho-TP motif present in cdc25C at T130 as a polo-box-
domain (PDB) binding motif [26, reviewed 27]. In Xenopus,
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11798phosphorylation of residues (T48, T67, T138 and S 287) changes
cdc25C activity and is required for normal mitosis [14,15]. Also in
Xenopus, phosphorylation of T138 is linked to an interaction with
PR56-delta subunit of phosphatase 2A (PP2A) [28] and may be
involved in mitotic exit [29]. At least one report has suggested that
T48 is phosphorylated by MAP kinase ERK2 [30]. In humans,
residues T48, T67, T130 and S214 are in TP/SP motifs
susceptible to phosphorylation by cdks, mitogen activated kinases,
CAM kinase II and GSK3 [31,30,32]. In human cdc25C, we
showed these sites could be phosphorylated by purified cdk1/
cyclin B in vitro and were phosphorylated in vivo in mitotic cells
[17]. Phosphorylation of cdc25C on SP/TP motifs is associated
with cis-trans proline isomerization by PIN1 necessary for
phosphatase activation [reviewed 33, 34, 35]. Incubation of
human cdc25C with Xenopus mitotic extracts also increased
phosphatase activity leading to a model where an auto-
amplification loop involving cdc25C and cdk1/cyclin B may be
implicit in mitotic activation [16].
Here, we have investigated the site-specific phosphorylation of
cdc25C on proline directed threonines 67 and 130, and the
cytolocalization and timing of these phosphorylations in dividing
human cells. Using site-specific affinity purified antibodies for
these sites, we show they are phosphorylated in mitotic cells but in
distinct pools of cdc25C with different cytolocalization.
Results
Anti-phospho-site antibodies are specific for single TP phos-
phorylation events.
Human cdc25C is phosphorylated on three TP motifs (T48,
T67 and T130) and one SP motif (S214) during mitosis in human
cells [17]. In order to analyze the potential role for phosphory-
lation of the N-terminal of cdc25C during human mitosis we
developed antibodies specific for the three phospho-TP motifs
using 9 amino acid peptides as shown in Supplemental Figure
S1A. After double affinity purification each antibody was tested by
western blotting. To demonstrate that the antibodies were specific
for the phosphorylated peptide, we incubated the affinity purified
antibodies with the phospho-peptide antigen or the non
phosphorylated peptide before blotting. As shown in Figure 1A,
only the phospho-peptide antigen specifically blocks reactivity for
each antibody by western blot against Hela cell extracts. Anti-
pT48 reacts with a number of protein bands from 59–80 kDa
whereas anti-pT67 and anti-pT130 react with discrete bands
around 59kDa which in the case of pT67 may appear as a doublet.
We also obtained the same results when the non-phospho-peptide
antigen was accompanied by phospho-threonine and/or the two
other phospho-peptides (pT67, pT130 for anti-pT48, pT48 and
pT130 for anti-pT67 and pT48 and pT67 for anti-pT130)
effectively excluding the possibility that our antibodies react with
anti-phospho-T or phospho-T-proline motifs (data not shown).
To confirm that these phospho-site directed antibodies were
specific for cdc25C, we next compared the protein patterns between
normal asynchronous Hela extracts and extracts from Hela cells in
which cdc25C had been ablated by RNA interference [36]. As shown
in Figure 1B, anti-pT67 and anti pT130 recognize discrete bands
similar to those shown in Figure 1 in cells transfected with non-
specific siRNA duplexes and these bands are absent in extracts from
cells transfected with siRNA to cdc25C. In contrast, the anti-pT48
reacts with 3 proteins of molecular masses ranging from 85 to 50 kDa
only two of which are effectively reduced by siRNA to cdc25C. The
same results were obtained with 3 different RNA duplexes [36,37]
used either alone or in combination. Furthermore, these same non
specific bands were observed in U2OS cells and are unlikely to be
spliced forms since, they also exist in non-transformed cells and the
Lindquist siRNA is directed against a sequence present in all 5 spliced
forms described to date. They are also present in the commercially
available anti-pT48 (data not shown). Perhaps explaining the
persistence of these bands after siRNA-cdc25C treatment, a motif
search for the phospho-epitope peptide antigen for pT48 against the
primate protein database, retrieved an entirely conserved sequence in
the human inositol bi-phosphatase kinase 5 YVLE (PIP3K5), of
which 4 forms 90, 75, 60 and 50 kDa are present in Genbank
primate (N. lamb and A. Fernandez unpublished observation).
Wenext confirmed the specificity for each phospho-site on cdc25C
by reacting the antibodies with Wt and alanine mutant cdc25C
proteins phosphorylated in vitro by cdk1/cyclin B1. As shown in
Figure 1C, anti-pT67 reacts with phosphorylated WT, T48A and
T130A cdc25C but does not react with T67A mutant cdc25C.
Similarly, anti-pT130 reacts with phosphorylated WT, T48A, T67A
but not T130A cdc25C. The phosho-specific antibodies do not react
with cdc25C unless it has been phosphorylated (Supplemental Figure
S1B). The apparent differences in anti-phospho-antibody reactivity to
the in vitro phosphorylated proteins shown in Figure 1C do not
represent a differential sensitivity of the antibodies for the different
alanine mutants but more likely the variable stability of the alanine
mutant proteins. As shown in Figure S1C, when overall levels of anti-
phospho-antibody staining are normalized to the levels of cdc25
present in the samples, the levels of phosphorylation of the Wt and
mutant proteins are very similar. Moreover, the reactivity of the
antibodies with phospho-cdc25C is completely abolished if cdc25C is
briefly incubated with alkaline phosphatase for 5 minutes (data not
shown). From these data we can conclude that anti-pT67-cdc25C
and anti-pT130-cdc25C antibodies react exclusively and specifically
with single phosphorylated epitopes on human cdc25C.
To confirm the existence of cdc25C phospho forms in other cells
types, we analyzed extracts from asynchronous transformed U2OS
andnormalnon-transformedhumanfibroblast.AsshowninFigure1,
panel D, both pT67 and pT130 have similar blotting patterns in
extracts of U2OS and non transformed fibroblast cells as those
observed in Hela.
Finally, we analyzed the profile for each phospho-site anti-
cdc25C in synchronized Hela cells. Figure 1E, shows that while
the phosphorylation of pT67 and pT130-cdc25C is present in
asynchronous cell extracts, it is absent from extracts of cells
blocked in S-phase. The signal for pT67 is not present in late G2
cells (TT+8) but strongly stains extracts from mitotic cells. Anti-
pT130 also strongly reacts with asynchronous and mitotic extracts
and not S-phase blocked cells. However, unlike pT67 antibodies,
pT130 also reacts with cdc25C in extracts from late G2 (TT+8)
suggesting that this site is phosphorylated earlier in mitosis. These
data demonstrate the specificity of these two antibodies for single
phospho-epitopes on human cdc25C.
Different cytolocalization for anti-phospho-cdc25C pT67
And pT130
We next analyzed the cytolocalization of anti-pT67 and anti-
pT130 in synchronized human fibroblasts (the same cells as
blotted in Figure 1D). As shown in Figure 2, anti-pT67 does not
react with cells in G1/S-phase and only becomes visible in cells in
late G2 (Figure 2, arrowed) or entering mitosis (prophase) where it
localizes in the nuclear compartment. The signal in the mitotic cell
is specific for pT67 since pre-incubation of the antibodies with
phospho-peptide (but not non-phosphorylated peptide) before use
completely abolishes the signal in the mitotic cells (Figure S2).
More detailed analysis of mitotic cells (Figure 3), shows that pT67-
cdc25C is closely associated with the chromatin from prophase
until the end of telophase. Furthermore, a similar chromatin
Phospho-cdc25C in Mitosis
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S3). In a manner similar to anti-pT67, anti-pT130-cdc25C does
not detect any signal in G1 or S-phase cells (Figure 4) or in G2 cells
until the entry into mitosis. At this time, in contrast to anti-pT67,
in addition to the general increase in pT130 staining, anti-pT130
localizes at two distinct points reminiscent of the centrosomes
(arrowed Figure 4F). In a manner similar to anti-pT67, the signal
for pT130 is specifically abolished by pre-incubation of the
antibodies with the phospho-peptide antigen but not the non-
phospho-peptide antigen (Figure S4) and is found in other cell
types such as U2OS (Figure S4, E and F) or Hela (data not shown).
More detailed analysis during mitosis (Figure 5), confirms that
pT130-cdc25C localizes primarily at the spindle poles throughout
mitosis until the end of anaphase. Staining normal human cells for
endogenous cdc25C (Figure S5) reveals that both nuclear and
spindle pole cytolocalization for phospho-cdc25C are detected in
normal mitotic cells. We have also microinjected siRNA duplexes
to cdc25C into human fibroblasts and confirmed that the signal for
both phospho-forms of cdc25C was abolished by cdc25C knock-
down, although since siRNA injected cells are blocked before
entering mitosis, this result is to be expected (data not shown).
These data further show that cdc25C molecules are specifically
phosphorylated on these two sites only at mitosis and for the first
time that these phospho-isoforms of cdc25C have specific spatially
distinct localizations in mitotic cells.
Human cdc25C is mono-phosphorylated on TP/SP motifs
at mitosis
The discovery that different phospho-cdc25C isoforms have
distinct localizations lead us to question whether cdc25C was
uniquely phosphorylated on the different TP sites. We immuno-
precipitated each endogenous phospho-cdc25C isoforms from
Figure 1. Phospho-cdc25C antibodies are specific for each cdc25C phospho epitope. Panel A: Extracts from asynchronous Hela cells were
analyzed by western blotting using double affinity purified anti-phospho-cdc25C antibodies. Shown are typical protein patterns recognized by anti-
pT48 (pT48), anti-pT67 (pT67) and anti-pT130 (pT130) in extracts from asynchronous cells (As) and the same extracts after the antibodies were pre-
incubated for 1 hour in 50 ug/ml of the non-phosphorylated peptide epitope (+Pep) or the phosphorylated peptide epitope (+Pep-P*). Molecular
masses are in kDa. Panel B: RNA interference specifically ablates the signal for pT67 and pT130 epitopes: Hela cells were transfected with siRNA
targeting cdc25C and 24 hours after harvested and analyzed for the expression of cdc25C (H150) and signals for pT48, pT67 and pT130. Shown are
typical western blot patterns. Also shown are loading controls (anti-alpha-tubulin). Panel C. Anti-phospho-cdc25C antibodies are specific for single
phosphorylation sites on cdc25C: cdc25C Wt and alanine mutant proteins were expressed in bacteria and after purification phosphorylated in vitro
using purified cdk1/cyclin B1. Shown are the western blots for WT, T48A, T67A and T130A cdc25C blotted with anti-cdc25C (H150, pT48, pT67 and
pT130). Panel D. Phospho-cdc25C isoforms are present in human cells of different types. Extracts were prepared from transformed U2OS cells or
normal human fibroblasts (T11-HT) and analyzed for phosphorylation of cdc25C. Shown are typical western blot of asynchronous cells profiles stained
for anti-pT67, anti-pT130 and anti-cdc25C (T150). 50 ug total protein extract/lane. Panel E. Limited cell cycle analysis of the phosphorylation patterns
for cdc25C in Hela cells. Cells were asynchronous (as), at S-phase (TT), late G2 (G2/M) or mitosis (M). Shown are western blots for pT67, pT130, cdc25C
(H150), cyclin B1 and tubulin.
doi:10.1371/journal.pone.0011798.g001
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by western blot, re-probed the three precipitates with each
phospho-specific antibody or anti-cdc25C. Throughout the
immunoprecipitation process, cell extracts were incubated with
antibodies in the presence of phosphatase inhibitors (Okadaic acid,
Tautomycin and calyculin A) and phosphatase attenuators, PBS,
beta-glycero-phosphate, sodium vanadate and fluoride (c.f.
Materials and methods). As shown in Figure 6A, each phospho-
isoform reacts only with itself and not with any proteins
precipitated by the other three antibodies. In addition, the
proteins immunoprecipitated by each of the anti-phospho-
antibodies and recognized by these antibodies were also
recognized by anti-cdc25C C20. The lack of additional bands
previously detected by immunoblot with anti-pT48 (Fig 1A) is
Figure 2. Cdc25C is phosphorylated on threonine67 only in mitosis and localizes in the nucleus in prophase. Human fibroblasts were
synchronized by serum deprivation and fixed in G1/S (16 hours after refeeding) and at G2/M (26 hours post refeed). Cells were stained for DNA (A, B),
anti-cdc25C-pT67 (C,D) and tubulin (E,F). Shown are representative fluorescence photo micrographs of staining in G1/S phase cells (panels A, C, E)
and G2/M phase cells (panels B, D, F). Phospho-pT67 staining is absent from G1 cells but present in the nucleus of late G2 (arrowed in D) or prophase
cells. Bar 10 uM.
doi:10.1371/journal.pone.0011798.g002
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immunoprecipitation removing the cell membranes and associated
membrane bound PIP3K5 in the insoluble fraction. These data
show for the first time that the 3 TP mitotic phosphorylation sites
in human cdc25C are only phosphorylated on a single TP motif
and not simultaneously phosphorylated on the other two TP
motifs.
The cytolocalizations observed for pT67-cdc25C and pT130-
cdc25C are similar to those described for a number of mitotic
factors including MPM2 antigens [38], Plk1 and gamma-tubulin.
We therefore probed the immunoprecipitates of endogenous
anti-pT67 and anti-pT130 for the presence of other interacting
proteins. As shown in Figure 6B and C, phospho-T67-cdc25C is
associated with MPM2 reactive proteins, but not with Plk1 and
this association was observed both by precipitating MPM2 or
pT67-cdc25C. In contrast, pT130-cdc25C co-precipitated Plk1
but not MPM2 proteins. These co-immunoprecipitation exper-
iments further show that anti-pT67 cdc25C is not associated
with pT130 cdc25C and vice versa. The association of pT130-
cdc25C with Plk1 is consistent with the localization of Plk1 [39]
and homology between the phospho-T130 motif and the
previously identified polo-box domain (PBD) binding motif
[26, reviewed 27]. We therefore examined if mutation of the
putative PBD motif in cdc25C interfered with the interaction
with Plk1. As shown in Figure 6D when HA-tagged cdc25C
expressed in U2OS cells is immunoprecipitated through the HA-
tag, Plk1 is associated with the tagged protein. In contrast, when
immunoprecipitates of HA-tagged cdc25C-T130A are probed
for Plk1, the signal is less than 10% of that observed for the Wt
despite the HA-tagged proteins being expressed at quantitatively
similar levels. These data show that not only are the phospho-
isoforms differently localized in mitotic cells and not simulta-
neously phosphorylated, but they are also associated with
different protein partners. This association is also seen by
indirect immunofluorescence. As shown in Figure 7, when
normal fibroblasts are simultaneously stained for MPM2
antigens and pT67-cdc25C a proportion of the staining for
MPM2 antigens overlaps with that of pT67-cdc25C around the
condensed chromatin. However, the staining for the MPM2
antigens, which also recognizes the centrosome, does not overlap
with that of anti-pT67-cdc25C (arrowed in Figure 7).
Phospho-T130-cdc25C is localized at the centrosome
To confirm the centrosomal localization of cdc25C-pT130, we
undertook detailed confocal analysis of Plk1 and pT130-cdc25C
cytolocalization under different conditions. As shown in Figure 8,
at metaphase, Plk1 and pT130-cdc25C are perfectly superimposed
at the spindle poles. Interestingly, the Plk1 associated with the
centromeres at metaphase (Plk1 staining of the internal ring of
chromosomes) is not associated with pT130-cdc25C. To confirm
that pT130 was truly present at the centrosomes, we performed
co-localization of pT130-cdc25C with gamma-tubulin. As shown
in Figure 9, the gamma-tubulin and pT130-cdc25C staining
superimpose at the spindle poles. Moreover, (Figure 10), pT130-
cdc25C remains associated with the centrosomes even when cells
are chilled to 4uC for 60 minutes to disrupt the microtubule
network and spindle. In contrast, under similar low temperature
conditions (4uC, 60 or 120 minutes) Plk1 no longer localizes at the
centrosomes even though cdc25C-pT130 staining remains robust
(Supplemental Figure S6). These data confirm that pT130-cdc25C
is a phospho-form of cdc25C associated with the centrosomes and
spindle poles during mitosis in human cells.
Figure 3. Threonine 67 cdc25C is phosphorylated during mitosis and associates with the condensed chromatin. Asynchronous normal
human fibroblasts were fixed and stained for DNA (panels A, D, F, H), anti-cdc25C-pT67 (panels B, E, G, I) and tubulin (panel C). Shown are
fluorescence photo micrographs of typical staining patters in cells in prometaphase (A–C), metaphase (D–E), anaphase A (F–G) and anaphase B (H–I).
Bar 5 uM.
doi:10.1371/journal.pone.0011798.g003
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deprivation and fixed in G1 (12 hours after refeeding), S-phase (17 hours after refeeding) and at G2/M (26 hours after refeeding). Cells were stained
for DNA (A,C,E) and anti-pT130-cdc25C (B,D,F). Shown are fluorescence photo micrographs of typical staining patterns of cells in G1 (panels A–B), S-
phase (panels C–D) and G2/M (panels E–F). Staining for pT130-cdc25C is absent from G1 and S-phase cells (panels B and D) but present in the nucleus
of prophase cells (panel F). Arrowed are the positions of the two centrosomes in panel F. Bar 5 uM.
doi:10.1371/journal.pone.0011798.g004
Figure 5. Human cdc25C phosphorylated on threonine 130 localizes to the centrosome during mitosis. Asynchronous normal human
fibroblasts were fixed and stained for DNA (panels A, C, E, G), anti-cdc25C-pT130 (panels B, D, F, H). Shown are fluorescence photo micrographs of
typical staining patterns of cells in prometaphase, (A–B), metaphase(C–D), anaphase A (E–F) and anaphase B (G–H). An early prophase cell is also
visible in panels G and H). Bar 5 uM.
doi:10.1371/journal.pone.0011798.g005
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phosphorylatable mutant forms of cdc25C into U2OS cells and
scoring mitotic progression. As shown in Figure 11A, wild type
cdc25C, the phosphatase inactive C377S, T67A and T130A HA-
tagged cdc25C mutant forms are expressed at equal levels after
transfection. We then scored the mitotic stage of the HA-expressing
cells for either cells entering mitosis (prophase-metaphase) or cells
exiting from mitosis (anaphase A to telophase). The overall
background mitotic index is around 20%. In cells transfected with
Wt-cdc25C, 10 to 12% where at some stage of mitotic entry and an
equal percentage in mitotic exit (data taken from 6 different
experiments). As to be expected, in cells expressing C377S-cdc25C,
a phosphatase inactive dominant-negative form of cdc25, no cells
were observed in mitotic exit, and less than 1% showed any form of
chromatin condensation. No cells were in prometaphase or
metaphase. No cells expressing either T67A-cdc25C or T130A-
cdc25C were observed in mitotic exit (anaphase-telophase). Cells
expressing T67A also showed a significant decrease in entering
mitosis with less than 4% of cells having condensed chromatin. Cells
expressing T130A-cdc25C had a 50% decrease in early mitotic
figures but were generally more rounded than cells transfected with
T67A. None of the cells expressing T67A or T130A wereobserved in
metaphase.Interestingly,whencellsexpressing onlylowlevelsofHA-
tagged cdc25C-T67A or T130A are examined, a proportion of the
endogenous cdc25C proteins still localize correctly while the
overexpressed alanine mutants do not (Supplemental Figure S7)
suggesting that these alanine mutants function as competitive
inhibitors restricting access of endogenous cdc25C to essential
Figure 6. Phospho-cdc25C isoforms are not phosphorylated on other TP sites and associate with different proteins. Panel A:
Phospho-cdc25C isoforms are exclusively phosphorylated on a single TP motifs at any one time. Phospho-cdc25C isoforms were immuno-
precipitated from Hela cells using anti-phospho-cdc25 antibodies directed against pT48, pT67 and pT130 and blotted for each phospho-isoform and
anti-cdc25C. Immunoprecipitates were separated by PAGE before transfer to nitrocellulose. Panels B and C; Extracts from mitotically enriched HeLa
cells were immunoprecipitated with anti phospho-cdc25C pT67 or pT130 before subsequently probing for associated proteins. Panel B shows a
typical membrane probed for pT67, MPM2 and pT130-cdc25C (left panel). Right panel shows the converse experiment in which MPM2 proteins were
immunoprecipitated and then probed for anti-MPM2, anti-pT67 or anti-pT130. Panel C shows a similar experiment immunoprecipitating anti-pT130-
cdc25C and probing for pT130-cdc25C, anti-Plk1 and anti-pT67 (left panel). Right hand panel shows the converse experiment immunoprecipitating
anti-Plk1 and probing for anti-Plk1, anti-pT130-cdc25C and anti-pT67-cdc25C. Panel D, HA-tagged cdc25C Wt and cdc25C-T130A were transfected
into Hela cells and allowed to express for 24 hours. HA-tagged proteins were immunoprecipitated from cells extracts in the presence of protease and
phosphatase inhibitors before PAGE and transfer. Membranes were probed for cdc25C expression (anti-C20) and the Plk1. Shown are an extract from
untransfected U2OS, immunoprecipitated HA-cdc25C-T130A (middle lane) and HA-cdc25C-Wt (right hand lane). Arrowed are the mouse heavy chains
and the position of Plk1.
doi:10.1371/journal.pone.0011798.g006
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or in non-transformed diploid fibroblasts (T11-HT). Taken together,
these data show that mitotic phosphorylation of cdc25C on T67 and
T130 perform essential functions in mitotic progression, and that
pT67-cdc25C and pT130-cdc25C isoforms have different localiza-
tions during human cell mitosis, are not simultaneously phosphor-
ylated on other TP sites and are associated with different protein
partners.
Discussion
We show here differential spatial localization of 2 phospho-
isoforms of cdc25C. We have developed mono-specific antibodies
to the proline-linked phosphorylation sites on human cdc25C
which are phosphorylated at mitosis. The antibodies demonstrate
for the first time that different phospho-forms of cdc25C exist
which have differential spatial organization during human mitosis
and associate with different partner proteins. Furthermore, each
phosphorylated isoform of cdc25C is not simultaneously phos-
phorylated on the other TP sites on the same cdc25C molecule.
Finally, we show that non-phosphorylatable mutant forms of
cdc25C impair mitotic progression in human cells. These data are
the first to identify that separate phospho-forms of cdc25C with
specific localizations and protein partners exist in human cells,
thus questioning the long standing model of an auto-amplification
mechanism involving cdc25C and cdk1 in mitotic activation.
Mono-specific phospho-site antibodies to human cdc25C
We have developed antibodies to the proline dependent kinase
motifs T48P, T67P, T130P which we have previously identified as
being phosphorylated during human mitosis [17] and two of
which: T67 and T130 are highly conserved in cdc25C from
different species (Fig. S1). While each of the antibodies are highly
specific for the corresponding phosphorylated peptide antigen,
RNA interference knockdown of cdc25C shows that antibodies
against T48 react with phospho-proteins other than cdc25C.
Stringent database searching with hexamer peptide sequences
corresponding to the antigen sites identified protein families with
hexamer sequences corresponding to antigens for pT48 and
pS214. The first family, phosphatidylinositol-3- phosphate/
phosphatidylinositol 5-kinases (PIKFyve), harbor the sequence
PRTPVG comprising 6 of the 9 amino acids in the pT48 antigen.
In Xenopus, the equivalent site on cdc25C has been proposed to
be a substrate for MAP kinases [30]. The same study reported the
phosphorylation of GST-human cdc25C in vitro by MAP kinase
ERK2, recognition of this phospho-motif by a commercial
antibody and a reduction in human cdc25C T48 phosphorylation
after inhibition of MAP kinase ERK2 with UO126. In our hands,
the commercial antibody directed against human pT48-cdc25C
used by these authors detects the same none cdc25C proteins as
our anti-pT48 in particular those not ablated by siRNA both by
western blotting and immunofluorescence likely to correspond to
PIKFyve family proteins (CF, NL unpublished observation). In
addition, it is unlikely that MAP kinase phosphorylates T48 in
human cdc25C during normal cell mitosis since active MAP
kinase cannot be detected in mitotic Hela cells in the absence of
drug-induced microtubule destabilization [40].
We show here that human cdc25C phosphorylated on T130 is
localized at the centrosomes during mitosis in both normal and
transformed cells. Furthermore pT130-cdc25C phospho form
Figure 7. Immunofluorescence staining for anti-pT67 and MPM2 partially overlap around the chromatin. Asynchronous human
fibroblasts were probed by double immunofluorescence for MPM2 antigens and pT67-cdc25C. Shown are typical fluorescence micrographs of
staining for DNA, MPM2 and pT67-cdc25C. Side panels show a limited region of each image and the images overlapped. Arrowed are the position of
the centrosome stained only by anti-MPM2.
doi:10.1371/journal.pone.0011798.g007
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phosphorylate cdc25C on serine 198 [21]. We have observed spindle
pole-centrosomal localization of endogenous cdc25C in mitotic
human fibroblasts (Figure S5) and ectopically expressed fluorescent
human-cdc25C has been reported to localize at the centrosomes [22].
In Xenopus, phosphorylation of T138 (the equivalent site) is
important for the interaction of cdc25C with phosphatase type 2A
[28]. The interaction of these two endogenous proteins Plk1 and
pT130-cdc25C we showed here demonstrates in living human cells
that the polo box domain (PBD) binding motif previously identified
from in vitro screening analysis [26] is a functional PBD binding site.
Indeed, incubating lysed cell models with a peptide containing a
similar motif interfered with Plk1 localization at the centrosome [26].
We have also observed that phosphorylation of cdc25C-pT130 is
essential to Plk1 localization at the centrosomes since microinjection
of the phospho-peptide disrupts Plk1 localization (NL, AF unpub-
lished observations). Furthermore, the T130A mutated form of
cdc25C is significantly impaired in its interaction with Plk1 as shown
by the very low signal for Plk1 associated with the HA-tagged
cdc25C-T130A immunoprecipitate when compared to Wt HA-
tagged-cdc25C. However, the observation that anti-cdc25-pT130
can immunoprecipitate the Plk1 raises the question of how our
antibody and Plk1can besimultaneously binding to the same epitope.
One likely answer is that cdc25C-pT130 and Plk1 are part of a much
larger complex of proteins associated with the centrosome or that
cdc25C acts as in a multimeric form. We have biochemical data to
support that human cdc25C is dimeric or tetrameric in U2OS and
Hela cells (NL. CF unpublished data) and the presence of signal for
Plk1 (albeit relativelylow) observed when HA-tagged-cdc25C-T130A
is immunoprecipitated is consistent with existence of Wt-T130A
complexes. The detailed biochemical characterization of phospho-
cdc25C complexes is currently in progress.
The centrosomal localization of phospho-cdc25C is resistant to
microtubule destabilization by cold showing true centrosomal
localization of pT130-cdc25C, i.e. not dependent upon intact spindle
poles. Interestingly cdc25B has also been implicated in modulation of
cdk1 activity at the centrosome [41] and has recently been identified
as a substrate for Plk1 [42]. The observation that phospho-pT130
form of cdc25C is the form localized to the centrosomes and acts to
anchor Plk1 at this site offers the interesting possibility that cdc25C is
involved in the modulation of cdc25B by Plk1. Indeed, cdc25B does
not posses a potential phosphorylated motif to bind PBD as present in
pT130-cdc25C.
Non-phosphorylatable cdc25C mutants block
proliferation and delay mitotic progression
We show that expression of non-phosphorylatable (T67A and
T130A) forms of cdc25C in U2OS inhibit cell cycle progression at
mitosis in a manner similar to the dominant negative phosphatase
inactive C377S form of cdc25C (Figure 11). For T130A-cdc25C
Figure 8. Phospho-pT130-cdc25C and Plk1 co-localize at the centrosomes but not at the centromeres. Normal human fibroblasts were
stained for DNA, Plk1 and phospho-T130-cdc25C. Shown are the staining for DNA alone, pT130-cdc25C alone, Plk1 alone, pT130-cdc25C and Plk1
overlapped and all three staining patterns overlapped.
doi:10.1371/journal.pone.0011798.g008
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for non transfected cells or cells transfected with WT cdc25C
(Figure 11). At low levels of expression, neither cdc25C-T67A nor
T130A disrupt the localization of endogenous cdc25C (Figure S7),
suggesting that the effects of higher levels of expression on mitosis
transit are due to competitive inhibition. The implication of
cdc25C in cell cycle transit, checkpoint signaling and mitotic
activation has been well established over a considerable period of
time [11,9]. However, Lindquist and coworkers [37] reported only
a transient delay in Hela cells microinjected with siRNA targeting
cdc25C and suggested that cdc25C was not essential to mitosis in
highly transformed cells. In our hands, microinjection of either the
siRNA sequences described by Lindquist et al., [37] or our own
[36] at 10 nM in the needle, ca,1.0 nM in the cell together with
plasmids expressing EGFP as marker was accompanied by a
complete absence of mitotic cells and no staining for either pT67
or pT130 in both U2OS or normal diploid fibroblasts (data not
shown). Varmeh & Manfred [43], demonstrated that overexpres-
sion of cdc25C sensitized U2OS cells to deoxyrubicin an effect not
seen in non-transformed cells. Overexpression of cdc25C did
however, block non transformed cells at the G1/S boundary [43].
However, these authors also reported that RNA interference for
cdc25C failed to block cell cycle progression in transformed U2OS
cells using liposome based transfection. As we described previously
[36], one of the most difficult aspects of RNA interference for
cdc25C stems from obtaining a complete ablation of the cdc25C
signal. Both Lindquist et al., [37] and Varmeh & Manfredi [43]
demonstrate a complete loss of cdc25A protein expression by
western blot while still showing residual protein expression for
cdc25C. Using calcium phosphate (as opposed to liposomal
Figure 9. Anti-phospho-pT130-cdc25C localization coincides with staining for anti-gamma tubulin. Normal human fibroblasts were
fixed and stained for DNA (panels A–D), anti-pT130 (panels E–H) and anti-gamma tubulin (panels I–L). Shown are photo micrographs of typical
staining patterns in cells in prophase (panels A, C, I), prometaphase (panels B, F, J), metaphase (panels C, G, K) and anaphase (D, H, L). Bar 5 uM.
doi:10.1371/journal.pone.0011798.g009
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cdc25A and C expression [36]. Erikson and co-workers also
recently described that differential penetration of shRNA also lead
to variable mitotic inhibition extending from a short mitotic delay
to mitotic catastrophe [44]. While the difficulties in depleting cells
completely from cdc25C could in part explain these discrepancies
in the requirement for cdc25C for mitosis, an alternative
explanation may come from the cell lines used in these studies.
The effectiveness of RNA interference for Plk1 was highly
dependent on the transformed state of the cell lines used. In
highly transformed cells, Plk1 ablation results in cell cycle delay
[45] whereas the requirement for Plk1 in non-transformed cells
only becomes visible only after clonal selection [44]. From these
data, it would appear that cdc25C is an essential component to
normal cell mitosis where it likely acts as a checkpoint agent as
suggested in prior studies. With increasing levels of transformation,
the importance of these checkpoints is reduced as the conse-
quences of aneuploidy is over-ridden by the drive for deregulated
growth. We are currently examining if multiple alanine mutant
forms of cdc25C disrupt mitosis in more transformed cells.
Finally, show here for the first time that different phospho-forms of
h u m a nc d c 2 5 Ce x i s ti nm i t o t i cc e l l s ,t h a ta r en o ts i m u l t a n e o u s l y
phosphorylated on the 3 TP motifs phosphorylated during mitosis in
human cells [17]. One potential explaination for these observations is
that the binding of the antibody to the phosphorylated residue
protects it from threonine phosphatase activity which otherwise
dephosphorylates the other sites during the immunoprecipitation
process. However,this is highly unlikelyto be the casehere for at least
2 reasons: Firstly, the immunoprecipitations are performed in the
presence of a cocktail of phosphatase inhibitors including 1.0 uM
Okadaic acid, tautomycin and calyculin A as well as other
phosphatase attenuators such as beta-glycero-phosphate and ortho-
phosphate. Secondly, these observations are backed up by the finding
that 2 of the different phospho-forms have spatially separate
intracellular localizations during mitosis. Together, these data
effectively exclude that a multi TP/SP site amplification loop
involving cdk1/cyclin B1 and cdc25C exists in human mitosis.
Instead our data suggest the existence of phosphorylation-specific
forms of cdc25C with precise cellular localization and function. Our
data point to a radically different way in which cdc25C could
function in mitosis by targeting specific protein complexes to distinct
cellularsites.ThereisalreadysomepreviousdatainXenopusthatthe
pT138 form specifically associates with a subunit of phosphatase 2A
[28]. It now remains to further determine the nature of the different
partner proteins associated with each phospho-site and identify the
function of each cdc25C phospho-isoform.
Materials and Methods
Cell Culture and Immunofluorescence
Primary immortalized human fibroblasts, T11HT, a generous
gift from Dr. Vincent Mouly (Institut de Myologie, Paris) and
transformed Hela cells were grown in Dulbeccos MEM, sub-
cultured onto glass cover slips and synchronized as described
previously [36]. Cells were fixed, extracted and subject to indirect
immunofluorescence as described elsewhere [46,47].
Antibodies and immunization
Synthetic peptides corresponding to residues 44–52 (T48-
DVPRTPVGK and T48-DVPR-*TPVGK (chemically phosphory-
Figure 10. Centrosomal localization of pT130-cdc25C resists microtubule and spindle disassembly at 4uC. Normal human fibroblasts
were incubated at 4uC for 60 minutes before fixation and staining for DNA (panels A, D), anti-pT130-cdc25C (panels B, E) and anti-tubulin (panels C,
F). Shown are typical fluorescence photo micrographs of an untreated cell in prometaphase (panels A–C), and a polar view of a metaphase cell after
60 minutes at 4uC (panels D–F). Note the persistence of centrosomal staining in E with the absence of any microtubule spindle in F.
doi:10.1371/journal.pone.0011798.g010
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T67-LSGG-*TPKCC) and T130, 127–135 (T130-LCSTPNGLD)
and 127–135 (T130-LCS*TPNGLD) of human cdc25C were
conjugated with keyhole limpet heamocyanin and injected into
rabbits. Peptides were synthesized and coupled by Neosystems,
Strasbourg, France. Before immunoblotting, immunoprecipitation or
immunofluorescence, sera were double affinity purified on ECH
Sepharose 4B columns (Amersham Biosciences, Orsay, France)
coupled with the non-phosphorylated or immune phospho-peptides,
using the manufacturer’s instructions. All antisera where first passed
through the non immune- non –phosphorylated peptide column and
unbound antibodies subsequently bound and eluted from the
phospho-peptide column. Antisera were stored at 4uC, while purified
antibodies at 280uCi n5 %g l y c e r o l .
Immunoblots, transfection and immunoprecipitation
analyses
Total extracts from cells were electrophoretically separated on 10%
SDS-polyacrylamide gels and immunoblotted as previously described
[36]. Commercial primary antibodies against Plk1 and cdc25C (F8
and H150, Santa Cruz Biotechnology, Santa Cruz, CA), cdc25C
(N20, [36] were used at 1:500. Antibodies to MPM2 were used 1:500.
Affinity purified anti-phospho-cd25C specific antibodies were used at
1:1000 and anti-tubulin ascites (clone DM1A) at 1:10000. Mamma-
lian cells were transfected with Lipofectamine 2000 (InVitrogen Inc,
Les Ulis, France) according to the manufacturers instructions. All
immuno-precipitations were performed as described [36]. Essentially,
c e l l sw e r ew a s h e do n c ei ni c ec o l dP B Sb e f o r es c r a p i n ga n dc o l l e c t i o n
by centrifugation. Cell pellets were snap frozen at 270uCb e f o r el y s i s
in 50 mM Tris-CL (pH 7.5), 150 mM NaCl, 10mM Na-phosphate
(pH 7.5), 1.0% (v/v) NP40, 0.5% (v/v) deoxycholate, 0.5% (v/v)
Triton X100, 1.0 uM Okadaic acid, 50 uM Tautomycin, 50 uM
Calyculin A, 50 mM beta-glycero-phosphate, 10 mM NaF and 2mM
Na-Vanadate. This buffer was used throughout except for the final
washing of the antibody-protein-A-bead complexes which were
washed in PBS (150 mM Na-phosphate, 20 mM K-phosphate,
pH 7.5) supplemented with 1.0 uM Okadaic acid, 50 uM Tautomy-
cin, 10 nM Calyculin A, 50 mM beta-glycero-phosphate, 10 mM
NaF and 2mM Na-Vanadate.
Immunofluorescence
For immunofluorescence, cells were fixed in 3.7% (v/v) formalin
in PBS or in –20uC methanol as described previously [36]. Anti-
phospho-site antibodies were diluted at 1:2000 for sera or 1:500
for affinity purified antibodies. Cells were mounted and photo-
graphed as described elsewhere [36].
Site directed mutagenesis
N-terminally HA-tagged human cdc25C (accession number
GB:M34065) in pECE was a generous gift from Dr. Franck
McKeon, Harvard Medical School. Plasmids were subjected to
PCR based site directed mutagenesis using the Quick-change
method (Stratagene, La Jolla, USA) according to the manufactur-
ers instructions. Complementary oligonucleotide pairs to:
Figure 11. Transient transfection of non-phosphorylatable mutants of cdc25C significantly delay mitosis. Asynchronous U2OS cells
were transfected with plasmids expressing HA-tagged Wt-cdc25C, catalytically inactive C377S-cdc25C, T67A-cdc25C and T130A-cdc25C. 24 hours
after transfection cells were fixed and stained for Ha-cdc25C and scored for transfection efficiency (percentage of transfected cells per 100 cells) and
mitotic figures. Mitotic entry: cells with condensed chromatin, centrosomal separation and spindle formation; or mitotic exit: cells with separated
chromatin, anaphase spindles or mid-bodies. Shown are the results of 6 typical separate transfection experiments. Also shown are fluorescence
micrographs of typical staining for anti-HA-T67A-cdc25C and HA-T130A-cdc25C expressing cells and the corresponding DNA staining.
doi:10.1371/journal.pone.0011798.g011
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AATTT-3),
T67A (5-GCATTTTGTCTGGAGGAgCtCCAAAATGTTG-
CCTCGATC-3),
T130A (5-CACAGCTTCTTTGTAGCgCTCCGAATGGT-
TTGGAC-3) where used.
The open reading frame of each mutant was sequenced entirely.
Bacterial expression vectors encoding 6His-cdc25CWt and each
T-A mutant were constructed in pET101d using the Topo
Challenge system (InVitrogen, Les Ulis, France) according to the
manufacturers instructions. Each plasmid was sequenced. Proteins
were expressed in in Bl21-DE3 and purified by standard nickel
chelating chromatography.
Supporting Information
Figure S1 Antigenic Peptides and in vitro phosphorylation of
cdc25C and mutant forms. Panel A: Multiple sequence alignments of
the 3 proline directed threonine phosphorylation sites on human
cdc25C phosphorylated at mitosis. Shown are 20 AA sequences at
each site in Xenopus, rat, mouse pig and human. Right hand of each
block of aligned sequences is the phospho-peptide used as antigen in
this study. Panel B: Typical western blot analysis of purified human
cdc25C protein using anti-pT48, anti-pT67 and anti-pT130 with (+)
or without (2) phosphorylation by cdk1/cyclin B1. Lower panels
show the same membranes blotted with anti-cdc25C. Panel C,
Purified cdc25C Wt, T48A, T67A and T130A were phosphorylated
in vitro and blotted for cdc25C or the anti-phospho-site antibodies.
For each protein, the intensity of the bands recognized by the anti-
phospho-antibodies was normalized to the staining for cdc25C
protein and plotted as a percentage of the overall cdc25C staining.
The results were obtained from 3 different experiments.
Found at: doi:10.1371/journal.pone.0011798.s001 (0.02 MB
PDF)
Figure S2 Staining for cdc25C phospho-T67 cdc25C is
specifically abolished by incubation with the phosho-peptide.
Asynchronous human fibroblasts were fixed and stained for DNA
(panels A, C) or anti-pT67-cdc25C (B and D). Anti-pT67
antibodies were incubated with the non-phosphorylated peptide
(B) or phosphorylated peptide (D). Shown are fluorescent photo
micrographs of metaphase cells in each panel. Bar 5 mM.
Found at: doi:10.1371/journal.pone.0011798.s002 (0.05 MB
PDF)
Figure S3 Staining for cdc25C phospho-T67 cdc25C is present on
chromatin in transformed cells. Asynchronous U2OS cells were fixed
and stained for DNA (panels A, C,E,G) or anti-pT67-cdc25C (B, D,
F, H). Shown are fluorescence photo micrographs of representative
cells in prophase (A–B), prometaphase (C–D), prometaphase and
metaphase (E–F) or anaphase B (G–H). Bar 5 mM.
Found at: doi:10.1371/journal.pone.0011798.s003 (0.12 MB
PDF)
Figure S4 Staining for cdc25C phospho-T130-cdc25C is
specifically abolished by incubation with the phosho-peptide and
centrosomal staining is present in transformed cells. Asynchronous
human fibroblasts were fixed and stained for DNA (panels A, C) or
anti-pT130-cdc25C (B and D). Anti-pT130 antibodies were
incubated with the non-phosphorylated peptide (B) or phosphor-
ylated peptide (D). Shown are fluorescence photo micrographs of
typical staining patterns in prophase cells in each panel. Panels E
and F show staining for pT130-cdc25C in late prometaphase and
metaphase U2OS cells. Bar 5 mM.
Found at: doi:10.1371/journal.pone.0011798.s004 (0.06 MB
PDF)
Figure S5 Endogenous cdc25C proteins are present in the nucleus
andonthecentrosomesofnon-transformedhumanfibroblastsduring
mitosis. Asynchronous human fibroblasts were fixed and stained for
DNA (panels A, D, G), cdc25C (B, E, H) and tubulin (C,F, I). Shown
are fluorescence photo micrographs of cells in early prophase, early
prometaphase and late prometaphase. Bar 5 mM.
Found at: doi:10.1371/journal.pone.0011798.s005 (0.11 MB
PDF)
Figure S6 cdc25C phosphorylated on T130 remains associated
with the centrosomes at low temperatures even after Plk1
localization has been lost: Asynchronous human fibroblasts were
fixed and stained for DNA (panels A–E), cdc25C-pT130 (F–J) and
Plk1 (K–O). Shown are fluorescence photo micrographs of cells in
different mitotic phases after incubation at 37uC (A,F,K) or at 4uC
for 60 minutes (B,G,L) or 120 minutes (C,H,M; D,I, N; and
E,J,O). Bar 5 mM.
Found at: doi:10.1371/journal.pone.0011798.s006 (0.05 MB
PDF)
Figure S7 Low levels of expression of mutated forms of cdc25C
does not perturb the localization of endogenous phospho-cdc25C
isoforms. Transformed U2OS cells were transfected with HA-
tagged cdc25C T67A or T130A. 24 hours after transfection, cells
were fixed and stained for the HA-tagged-cdc25C (panels A and
B), cdc25C-pT67 (panel C), cdc25C-pT130 (panel D) or DNA
(panels E and F). Shown are typical photo micrographs of cells
expressing low levels of HA-tagged cdc25C. Bar 5mm.
Found at: doi:10.1371/journal.pone.0011798.s007 (0.07 MB
PDF)
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